Response to Wu et al. — Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong

References

• Wu DB, Roberts C, Lee VW, Hong LW, Tan KK, Mak V, Lee KK. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong. Hum Vaccin Immunother 2016 February; 12(2):403-16; http://dx.doi.org/10.1080/21645515.2015.1067351
   PubMed Web of Science ®Google Scholar
• Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 2013 December 17; 32(1):133-45; http://dx.doi.org/10.1016/j.vaccine.2013.05.005
   PubMed Web of Science ®Google Scholar
• Nicholls TR, Leach AJ, Morris PS. The short-term impact of each primary dose of pneumococcal conjugate vaccine on nasopharyngeal carriage: Systematic review and meta-analyses of randomised controlled trials. Vaccine 2016 February 3; 34(6):703-13; http://dx.doi.org/10.1016/j.vaccine.2015.12.048
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012 March; 31(3):297-301; http://dx.doi.org/10.1097/INF.0b013e318247ef84
   PubMed Web of Science ®Google Scholar
• Public Health England. Pneumococcal disease infections caused by serotypes in Prevenar 13 and not in Prevenar 7. 2-10-2015. Date Accessed: 29-2-2016. Available at: https://www.gov.uk/government/publications/pneumococcal-disease-caused-by-strains-in-prevenar-13-and-not-in-prevenar-7-vaccine
   Google Scholar
• Public Health England. Pneumococcal disease infections caused by serotypes not in Prevenar 13 vaccine. 2-10-2015. Date Accessed: 29-2-2016. Available at: https://www.gov.uk/government/publications/pneumococcal-disease-caused-by-strains-not-covered-by-prevenar-13-vaccine/pneumococcal-disease-infections-caused-by-serotypes-not-in-prevenar-13-vaccine
   Google Scholar
• Jokinen J, Kilpi TM, Kaijalainen T, Syrjänen R, Ruokokoski E, Van Dyke M, Palmu AA. Indirect Effectiveness of Ten-valent Pneumococcal Haemophilus Influenzae Protein-D Conjugate Vaccine (PHiD-CV10) Against Oropharyngeal and Nasopharyngeal Carriage - FinIP Indirect Carriage study [Abstract P11]. Nordic Vaccine Meeting 2014, Apr 23; Bergen, Norway; p. 52
   Google Scholar
• Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, Virolainen-Julkunen A, Toropainen M, Nuorti JP. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children–a population-based study. PLoS One 2015; 10(3):e0120290; PMID:25781031; http://dx.doi.org/10.1371/journal.pone.0120290
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Welfare. Incidence of invasive pneumococcal disease in Finland. 9-6-2015. Date Accessed: 9-3-2015. Available at: https://www.thl.fi/en/web/thlfi-en/research-and-expertwork/projects-and-programmes/monitoring-the-population-effectiveness-of-pneumococcal-conjugate-vaccination-in-the-finnish-national-vaccination-programme/incidence-of-invasive-pneumococcal-disease-in-finland
   Google Scholar
• Institute of Environmental Science and Research Ltd (ESR). Invasive pneumococcal disease in New Zealand, 2013. Available at: https://surv.esr.cri.nz/PDF_surveillance/IPD/2013/2013AnnualIPDRpt.pdf
   Google Scholar
• Public Health Agency of Canada. National Laboratory Surveillance of Invasive Streptococcal Disease in Canada - Annual Summary 2013. 19-6-2015. Date Accessed: 9-3-2015. Available at: http://www.healthycanadians.gc.ca/publications/drugs-products-medicaments-produits/2013-streptococcus/index-eng.php
   Google Scholar
• Aljunid S, Maimaiti N, Ahmed Z, Muhammad Nur A, Md Isa Z, Azmi S, Sulong S. Economic impact of pneumococcal protein-D conjugate vaccine (PHiD-CV) on the Malaysian national immunization programme. Value in Health Regional Issues 2014 May; 3:146-55; http://dx.doi.org/10.1016/j.vhri.2014.04.008
   PubMedGoogle Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, Santos JB, de Moraes JC. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med 2014 June; 2(6):464-71; http://dx.doi.org/10.1016/S2213-2600(14)70060-8
   PubMed Web of Science ®Google Scholar
• Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine 2015 May 28; 33(23):2684-9; http://dx.doi.org/10.1016/j.vaccine.2015.04.005
   PubMed Web of Science ®Google Scholar
• Organización Panamericana de la Salud. Informe Regional de SIREVA II, 2006: datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis en procesos invasores. 2008. Washington, DC. Date Accessed: 29-2-2016. Available at: http://www1.paho.org/Spanish/AD/THS/EV/labs_Sireva_II_2006.pdf
   Google Scholar
• Organización Panamericana de la Salud. Informe Regional de SIREVA II, 2011: datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis en procesosinvasores. 2012. Washington, DC. Date Accessed: 29-2-2016. Available at: http://www.paho.org/hq/index.php?option=com_docman&task=doc_download&gid=19210&Itemid=270&lang=es
   Google Scholar
• Saraiva FO, Minamisava R, Vieira MA, Bierrenbach AL, Andrade AL. Vaccination Coverage and Compliance with Three Recommended Schedules of 10-Valent Pneumococcal Conjugate Vaccine during the First Year of Its Introduction in Brazil: A Cross-Sectional Study. PLoS One 2015; 10(6):e0128656; PMID:26061276; http://dx.doi.org/10.1371/journal.pone.0128656
   PubMed Web of Science ®Google Scholar
• Knol MJ, Wagenvoort GH, Sanders EA, Elberse K, Vlaminckx BJ, de Melker HE, van der Ende A. Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands. Emerg Infect Dis 2015 November; 21(11):2040-4; http://dx.doi.org/10.3201/eid2111.140780
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010; 10:4; PMID:20122261; http://dx.doi.org/10.1186/1471-2431-10-4
   PubMed Web of Science ®Google Scholar
• Mrkvan T, Hoet B, Adegbola RA, Van Dyke M, Hausdorff WP. Serotype 19A and the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV): lessons learned to date [Abstract no. 284]. European Society for Paediatric Infectious Diseases (ESPID) 2013. 2013 May 28; Milan, Italy. 2013
   Google Scholar
• Hausdorff WP, Hoet B, Adegbola RA. Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough. Expert Rev Vaccines 2015 March; 14(3):413-28; http://dx.doi.org/10.1586/14760584.2015.965160
   PubMed Web of Science ®Google Scholar
• Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreno RA, Nohynek H, Riley ID, Makela H. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009; (4):CD004977; PMID:19821336
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial. PLoS Med 2014 June; 11(6):e1001657; http://dx.doi.org/10.1371/journal.pmed.1001657
   PubMed Web of Science ®Google Scholar
• Kilpi TM, Palmu AA, Puumalainen T, Nieminen H, Ruokokoski E, Rinta-Kokko H, Moreira M, Hezareh M, Borys D, Schuerman L, et al. Effectiveness of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against hospital-diagnosed pneumonia in infants-FinIP trial [Abstract no. 134]. European Society for Paediatric Infectious Diseases 2013. 2013 May 20; Milan, Italy. 2013
   Google Scholar
• Afonso ET, Minamisava R, Bierrenbach AL, Escalante JJ, Alencar AP, Domingues CM, Morais-Neto OL, Toscano CM, Andrade AL. Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis 2013 April; 19(4):589-97; http://dx.doi.org/10.3201/eid1904.121198
   PubMed Web of Science ®Google Scholar
• Sigurdsson S, Kristinsson KG, Erlendsdottir H, Hrafnkelsson B, Haraldsson A. Decreased Incidence of Respiratory Infections in Children After Vaccination with Ten-valent Pneumococcal Vaccine. Pediatr Infect Dis J 2015 December; 34(12):1385-90; http://dx.doi.org/10.1097/INF.0000000000000899
   PubMed Web of Science ®Google Scholar
• Berglund A, Ekelund M, Fletcher MA, Nyman L. All-cause pneumonia hospitalizations in children <2 years old in Sweden, 1998 to 2012: Impact of pneumococcal conjugate vaccine introduction. PLoS One 2014; 9(11):e112211; PMID:25379659; http://dx.doi.org/10.1371/journal.pone.0112211
   PubMed Web of Science ®Google Scholar
• Lindstrand A, Bennet R, Galanis I, Blennow M, Ask LS, Dennison SH, Rinder MR, Eriksson M, Henriques-Normark B, Ortqvist A, et al. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine. Pediatrics 2014 December; 134(6):e1528-e1536; http://dx.doi.org/10.1542/peds.2013-4177
   PubMed Web of Science ®Google Scholar
• Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Kayhty H, Karma P, Kohberger R, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001 February 8; 344(6):403-9; http://dx.doi.org/10.1056/NEJM200102083440602
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000 March; 19(3):187-95; http://dx.doi.org/10.1097/00006454-200003000-00003
   PubMed Web of Science ®Google Scholar
• Cohen R, Biscardi S, Levy C. The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014. Hum Vaccin Immunother 2016 February; 12(2):277-84; http://dx.doi.org/10.1080/21645515.2015.1116654
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006 March 4; 367(9512):740-8; http://dx.doi.org/10.1016/S0140-6736(06)68304-9
   PubMed Web of Science ®Google Scholar
• Leach AJ, Wigger C, Hare K, Hampton V, Beissbarth J, Andrews R, Chatfield M, Smith-Vaughan H, Morris PS. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine. BMC Pediatr 2015; 15:162; PMID:26482232; http://dx.doi.org/10.1186/s12887-015-0483-8
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014 September; 14(9):839-46; http://dx.doi.org/10.1016/S1473-3099(14)70822-9
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Greenberg D, Givon-Lavi N, Dagan R. Serotype-specific PCV7/PCV13 effect on invasive pneumococcal disease (IPD) in children <5 years in Israel, July 2004-June 2013 [ISPPD-0183]. 9th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). 2014 Mar 9; Hyderabad, India. 2014
   Google Scholar
• Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol 2013 December; 59(12):778-88; http://dx.doi.org/10.1139/cjm-2013-0614
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Dalby T, Weinberger DM, Benfield T, Molbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014 October 15; 59(8):1066-73; http://dx.doi.org/10.1093/cid/ciu524
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO, Jr. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013 March; 32(3):203-7; http://dx.doi.org/10.1097/INF.0b013e318275614b
   PubMed Web of Science ®Google Scholar
• Moore M, Taylor T, Pondo T, Barnes M, Petit S, Holtzman C, Lynfield R, Schaffner W, Harrison L, Zansky S, et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease (IPD) among children <5 years old in the US [ISPPD-0467]. 9th International Symposium on Pneumococci and Pneumococcal Diseases. 2014 Mar 9; Hyderabad, India. 2014
   Google Scholar
• Savulescu C, Hanquet G. Effectiveness of higher valency conjugate vaccines on invasive pneumococcal disease in Europe: preliminary results of spidnet multicentre project [ISPPD-0562]. 9th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). 2014 Mar 9; Hyderabad, India. 2014
   Google Scholar
• Steens A, Bergsaker MA, Aaberge IS, Ronning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013 December 16; 31(52):6232-8; http://dx.doi.org/10.1016/j.vaccine.2013.10.032
   PubMed Web of Science ®Google Scholar
• Joint Committee on Vaccination and Immunisation. Minutes of the JCVI meeting, 1 Oct 2014. 2014. Date Accessed: 2-3-2016. Available at: https://app.box.com/s/iddfb4ppwkmtjusir2tc/1/2199012147/22846051967/1
   Google Scholar
• Fenoll A, Granizo JJ, Aguilar L, Gimenez MJ, Aragoneses-Fenoll L, Hanquet G, Casal J, Tarrago D. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009 April; 47(4):1012-20; http://dx.doi.org/10.1128/JCM.01454-08
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, Zansky SM, Rosen JB, Reingold A, Scherzinger K, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med 2016; 4(5):399–406
   PubMed Web of Science ®Google Scholar
• Wu DB, Chaiyakunapruk N, Chong HY, Beutels P. Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006-2014). Vaccine 2015 March 30; 33(14):1633-58; http://dx.doi.org/10.1016/j.vaccine.2015.01.081
   PubMed Web of Science ®Google Scholar
• Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making 2012 September; 32(5):722-32; http://dx.doi.org/10.1177/0272989X12458348
   PubMed Web of Science ®Google Scholar